Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 875 versus DISPERMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 875 versus DISPERMOX.
AUGMENTIN '875' vs DISPERMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking.
One 875 mg amoxicillin/125 mg clavulanate tablet orally every 12 hours.
Adults: 1 g (as amoxicillin 875 mg + clavulanate 125 mg) orally every 12 hours for 7-10 days.
None Documented
None Documented
Amoxicillin: 1-1.5 hours (may extend to 7-13 hours in renal impairment). Clavulanate: ~1 hour (may extend to 2.5-4.5 hours in renal impairment).
Terminal elimination half-life 1.5 hours; prolonged in renal impairment.
Amoxicillin: ~50-70% renal as unchanged drug, 10-20% biliary. Clavulanate: ~30-50% renal as unchanged, ~25% fecal.
Renal excretion 80% as unchanged drug, biliary/fecal 10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic